On top of strong efficacy data, Alder migraine med shows potential

Shares of Alder Therapeutics ($ALDR) spiked 55% when the company released promising Phase IIb study data of its intravenous candidate for treating migraines. While approval is the foremost topic on investor's minds at the moment, success in the commercial arena will require differentiation in light of promising efficacy data from a similar Phase IIb Teva ($TEVA) candidate; Eli Lilly ($LLY) and Amgen ($AMGN) are also in the game. Luckily, the company also posted strong Phase I results of a, you guessed it, drug delivery study, which indicated that intravenous, subcutaneous or intramuscular injection could enable a quarterly dosing strategy. In addition to longer intervals between drug administration, patients often prefer subcutaneous or intramuscular injections to intravenous infusions. Convenience is key when it comes to commercialization. More from FierceBiotech | Release

Suggested Articles

Takeda forged a feasibility pact to see whether it could pair a plasma-based therapy with Elektrofi's microparticle delivery tech.

RNA nanoparticles can squeeze into tumors and exit swiftly through the kidney, perfect for targeted delivery of cancer drugs, an OSU team says.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.